来自低剂量暴露的风险

Same author

[Not Available].

Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]·2016

Same author

A prospective randomised phase-II trial with gemcitabine versus gemcitabine plus sunitinib in advanced pancreatic cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIV.

European journal of cancer (Oxford, England : 1990)·2014

Same author

Differences in binding of epidermal growth factor to liver membranes of TCDD-resistant and TCDD-sensitive rats after a single dose of TCDD.

Environmental toxicology and pharmacology·2011

Same author

Phase II study of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients with locally advanced or metastatic pancreatic cancer.

Investigational new drugs·2010

Same author

MGMT gene promoter methylation correlates with tolerance of temozolomide treatment in melanoma but not with clinical outcome.

British journal of cancer·2010

Same author

10 Years CESAR Anticancer Drug Research - The 7th CESAR Annual Meeting 2009. Preface.

International journal of clinical pharmacology and therapeutics·2010

Same journal

Erratum for the Research Article "Detecting supramolecular organic nanoparticles during heat wave".

Science (New York, N.Y.)·2026

Same journal

Local signals, systemic decline.

Science (New York, N.Y.)·2026

Same journal

The mechanics of liver regeneration.

Science (New York, N.Y.)·2026

Same journal

Computing in a memory with physics.

Science (New York, N.Y.)·2026

Same journal

Retraction.

Science (New York, N.Y.)·2026

Same journal

Making time.

Science (New York, N.Y.)·2026

相关实验视频

来自低剂量暴露的风险

相关概念视频

[Not Available].

A prospective randomised phase-II trial with gemcitabine versus gemcitabine plus sunitinib in advanced pancreatic cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIV.

Differences in binding of epidermal growth factor to liver membranes of TCDD-resistant and TCDD-sensitive rats after a single dose of TCDD.

Phase II study of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients with locally advanced or metastatic pancreatic cancer.

MGMT gene promoter methylation correlates with tolerance of temozolomide treatment in melanoma but not with clinical outcome.

10 Years CESAR Anticancer Drug Research - The 7th CESAR Annual Meeting 2009. Preface.

Erratum for the Research Article "Detecting supramolecular organic nanoparticles during heat wave".

Local signals, systemic decline.

The mechanics of liver regeneration.

Computing in a memory with physics.

Retraction.

Making time.

相关实验视频

来自低剂量暴露的风险

相关概念视频

相关文章

[Not Available].

A prospective randomised phase-II trial with gemcitabine versus gemcitabine plus sunitinib in advanced pancreatic cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIV.

Differences in binding of epidermal growth factor to liver membranes of TCDD-resistant and TCDD-sensitive rats after a single dose of TCDD.

Phase II study of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients with locally advanced or metastatic pancreatic cancer.

MGMT gene promoter methylation correlates with tolerance of temozolomide treatment in melanoma but not with clinical outcome.

10 Years CESAR Anticancer Drug Research - The 7th CESAR Annual Meeting 2009. Preface.

Erratum for the Research Article "Detecting supramolecular organic nanoparticles during heat wave".

Local signals, systemic decline.

The mechanics of liver regeneration.

Computing in a memory with physics.

Retraction.

Making time.